Fluoroquinolones
Spectrum
Marbofloxacin
Mycoplasma spp. many Gram-positive and Gram-negative organisms but not anaerobes.
Active against Pasteurella spp. Staphylococcus spp. Pseudomonas spp. Klebsiella spp.
Escherichia coli, Salmonella spp. and Proteus spp.5
Enrofloxacin
Mycoplasma spp. many Gram-positive and Gram-negative organisms but not anaerobes.
Active against Pasteurella spp. Staphylococcus spp. Pseudomonas spp. Klebsiella spp.
Escherichia coli, Salmonella spp. Proteus spp. and Mycobacterium spp.5
Pradofloxacin
Gram-negative and Gram-positive organisms, anaerobes, Mycoplasma spp. Rickettsia spp. and Mycobacterium spp.31
Physicochemical properties
Highly lipophilic.3
Distribution3,4,7
Good distribution. Good at entering the central nervous system (CNS), the prostate and urine.
Pharmacokinetics
Antimicrobial
Cmax
Protein
binding
Volume of distribution
Metabolism & elimination
Terminal
half life
Absorption
Tmax
Marbofloxacin
In dogs:
1.5 µg/ml for oral or S.C. administration.9
AUC(0-24) 13 µg.h/ml in dogs for oral administration.32
In cats:
1.4 µg/ml for oral or S.C. administration.9
<10%.6
In dogs:
1.36L/kg.9
In cats:
1.48 L/kg.9
Renal and in faeces.6
In dogs:
14 hours.6
In cats:
10 hours.6
Close to 100% bioavailability.6
In dogs:
<1 hour for S.C. administration, <2 hours for oral administration.9
In cats:
1-2 hours for oral or S.C administration.9
Enrofloxacin
1.41µg/ml32
AUC(0-24) 8.7 µg.h/ml32
27%25
3-4 L/kg25
Renal and some metabolised to ciprofloxacin by the liver.25
In dogs:
4-5 hours.25
In cats:
6 hours.25
Bioavailability 80%.25
<1 hour25
Pradofloxacin
In dogs: 1.01 µg/ml and
AUC(0–24) 8.19 µg.h/ml.31
In cats following administration of tablets at the dose rate of 3 mg/ kg: 0.83 µg/ml and AUC(0–24) 4.14 µg.h/ml.31
In cats following administration of suspension at the dose rate of 5 mg/kg: 1.45 µg/ml and AUC(0–24) 6.21 µg.h/ml.31
29-37%.31
In dogs:
2.22L/kg.31
In cats:
4.5 L/kg.31
10 and 40% excreted in urine in cat and dog respectively, remainder probably in faeces.31
In dogs:
6.6 hours.31
In cats:
10 hours.31
In dogs almost 100%.6
In cats at least 70%.6
In dogs:
2.1 hours.31
In cats:
0.5–1.0 hours.31
Parameters for oral administration in dogs unless otherwise stated.
Side effects/contra-indications85
Side effects and contra-indications may vary between presentations. Some of those seen more frequently are included here but veterinary surgeons should always refer to the Summary of Product Characteristics (SPC) for full details before prescribing a product.
Side effects include gastrointestinal disturbances at higher doses.
In cats, some but not all commercially available fluoroquinolones may cause blindness or ocular lesions at higher doses.
In young animals fluoroquinolones can produce arthropathy.
Disclaimer: Indications and doses may vary between products. The antimicrobials listed may constitute an off licence use of the product and as such should only be used according to the ‘Cascade’, further details of which are available on the RCVS, VMD and NOAH websites. Veterinary surgeons are advised to carefully check the Summary of Product Characteristics (SPC) before prescribing a product and obtain informed owner consent where required.